Paola Neri

List of Publications by Year
in descending order

80 papers	2,861 citations	186209 28 h-index	168321 53 g-index
80 all docs	80 docs citations	80 times ranked	3713 citing authors

#	Article	IF	Citations
1	Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center. Revista De Investigacion Clinica, 2022, 74, .	0.2	0
2	Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, , 1-2.	1.4	0
3	Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood, 2021, 137, 232-237.	0.6	90
4	The impact of COVIDâ€19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A singleâ€center experience. European Journal of Haematology, 2021, 106, 340-345.	1.1	5
5	N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution. Annals of Hematology, 2021, 100, 2521-2527.	0.8	3
6	Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer. Science Advances, 2021, 7, eabg6045.	4.7	19
7	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 394-399.	0.2	11
8	Combined CCNE1 highâ€level amplification and overexpression is associated with unfavourable outcome in tuboâ€ovarian highâ€grade serous carcinoma. Journal of Pathology: Clinical Research, 2020, 6, 252-262.	1.3	33
9	Antiâ€myeloma potential of ruxolitinib in coâ€existing JAK2V617F â€positive smouldering myeloma and polycythaemia vera. British Journal of Haematology, 2020, 189, e114-e118.	1.2	2
10	Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. Frontiers in Oncology, 2020, 10, 636.	1.3	24
11	Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019007.	0.5	5
12	From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1). Journal of Medicinal Chemistry, 2019, 62, 5522-5540.	2.9	77
13	Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center. Leukemia and Lymphoma, 2019, 60, 3199-3203.	0.6	9
14	The Pandoraâ€™s box of thalidomide analogs and their substrates. Blood, 2019, 134, 105-106.	0.6	2
15	Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients. Blood, 2019, 134, 1793-1793.	0.6	0
16	Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e69-e75.	0.2	6
17	Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood, 2018, 132, 2546-2554.	0.6	110
18	Monoclonal Gammopathy of Clinical Significance - a Single Center Experience. Blood, 2018, 132, 4495-4495.	0.6	0

#	Article	IF	Citations
19	Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. Annals of Hematology, 2017, 96, 431-439.	0.8	25
20	CD86 regulates myeloma cell survival. Blood Advances, 2017, 1, 2307-2319.	2.5	15
21	Revised International Staging System Applied to Real World Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 511-518.	0.2	37
22	New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. Clinical Cancer Research, 2016, 22, 5959-5965.	3.2	39
23	Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant. Leukemia and Lymphoma, 2016, 57, 973-976.	0.6	6
24	Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight. Leukemia and Lymphoma, 2016, 57, 557-562.	0.6	5
25	Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial. Blood, 2016, 128, 120-120.	0.6	9
26	Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Expert Opinion on Biological Therapy, 2013, 13, S69-S82.	1.4	35
27	Localized Surface Plasmon Resonance Detection of Biological Toxins Using Cell Surface Oligosaccharides on Glyco Chips. ACS Applied Materials & Interfaces, 2013, 5, 4173-4180.	4.0	52
28	Inhibitory Mechanism of 10-Hydroxy-trans-2-decenoic Acid (Royal Jelly Acid) Against Lipopolysaccharide- and Interferon-Î²-Induced Nitric Oxide Production. Inflammation, 2013, 36, 372-378.	1.7	34
29	XPO1 Inhibition Disrupts Ribosomal Subunits Assembly and Induces Multiple Myeloma (MM) Cell Death. Blood, 2013, 122, 3165-3165.	0.6	25
30	Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma. Blood, 2013, 122, 1978-1978.	0.6	1
31	Lenalidomide Induces A Ribosomal Stress Response In Multiple Myeloma (MM) Cells. Blood, 2013, 122, 3161-3161.	0.6	0
32	Inhibitory effect of 10-hydroxy-trans-2-decenoic acid on LPS-induced IL-6 production via reducing IÎºB-Î¶ expression. Innate Immunity, 2012, 18, 429-437.	1.1	32
33	Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 776-796.	0.8	46
34	Recombinant Shiga Toxin B Subunit Can Induce Neutralizing Immunoglobulin Y Antibody. Biological and Pharmaceutical Bulletin, 2012, 35, 917-923.	0.6	5
35	Panobinostat for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 2012, 21, 733-747.	1.9	34
36	Inhibition of interferon-Î³-induced nitric oxide production by 10-hydroxy-trans-2-decenoic acid through inhibition of interferon regulatory factor-8 induction. Cellular Immunology, 2012, 273, 73-78.	1.4	19

#	Article	IF	Citations
37	Mechanism of inhibition of lipopolysaccharide-induced interferon-Î² production by 2-aminopurine. Molecular Immunology, 2012, 52, 299-304.	1.0	16
38	Lenalidomide Suppresses 5â€²-Cap-Independent C-MYC Translation in Multiple Myeloma Cells. Blood, 2012, 120, 3943-3943.	0.6	1
39	High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide. Blood, 2012, 120, 931-931.	0.6	8
40	Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library. Vaccine, 2011, 29, 5340-5346.	1.7	16
41	Integrin Î²7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood, 2011, 117, 6202-6213.	0.6	134
42	Bortezomib-induced â€œBRCAnessâ€•sensitizes multiple myeloma cells to PARP inhibitors. Blood, 2011, 118, 6368-6379.	0.6	125
43	A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients. Blood, 2011, 118, 987-987.	0.6	2
44	Specific Egg Yolk Immunoglobulin as a New Preventive Approach for Shiga-Toxin-Mediated Diseases. PLoS ONE, 2011, 6, e26526.	1.1	21
45	Bortezomib Impairs Myeloma Cells (MM) Homologous Recombination Through Inhibition of the E2-Ubiquitin-Conjugating Enzyme UBC13. Blood, 2011, 118, 1834-1834.	0.6	0
46	SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells. Blood, 2010, 116, 452-452.	0.6	0
47	A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 324-324.	0.6	0
48	Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biology and Therapy, 2009, 8, 648-653.	1.5	88
49	In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 1009-1020.	1.1	62
50	Multivalent Galacto-trehaloses: Design, Synthesis, and Biological Evaluation under the Concept of Carbohydrate Modules. Biomacromolecules, 2009, 10, 1846-1853.	2.6	24
51	Integrin Î²7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Migration and Survival.. Blood, 2009, 114, 949-949.	0.6	0
52	p38 mitogenâ€activated protein kinase inhibitor LY2228820 enhances bortezomibâ€induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. British Journal of Haematology, 2008, 141, 598-606.	1.2	53
53	In vivo antiâ€myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. British Journal of Haematology, 2008, 143, 520-531.	1.2	59
54	Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine, 2008, 26, 469-476.	1.7	13

#	Article	IF	Citations
55	A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine, 2008, 26, 2092-2099.	1.7	26
56	Neutralizing B-Cellâ€“Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model. Clinical Cancer Research, 2007, 13, 5903-5909.	3.2	122
57	Monovalent Gb3-/Gb2-Derivatives Conjugated with a Phosphatidyl Residue: A Novel Class of Shiga Toxin-Neutralizing Agent. Biological and Pharmaceutical Bulletin, 2007, 30, 1697-1701.	0.6	17
58	Neutralizing Activity of Polyvalent Gb₃, Gb₂ and Galactoâ€Trehalose Models against Shiga Toxins. Microbiology and Immunology, 2007, 51, 581-592.	0.7	25
59	Glycochips from Polyanionic Glycopolymers as Tools for Detecting Shiga Toxins. ChemBioChem, 2007, 8, 2117-2124.	1.3	35
60	Establishment of BCWM.1 cell line for WaldenstrÃ¶m's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Experimental Hematology, 2007, 35, 1366-1375.	0.2	61
61	TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.. Blood, 2007, 110, 3517-3517.	0.6	15
62	Modulation of Gene Expression Profile and In Vivo Anti-Myeloma Activity Induced by Valproic Acid, a Histone Deacytylase Inhibitor.. Blood, 2007, 110, 4790-4790.	0.6	0
63	Role of B-Cellâ€“Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. Cancer Research, 2006, 66, 6675-6682.	0.4	212
64	Aggresome induction by proteasome inhibitor bortezomib and Î±-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood, 2006, 108, 3441-3449.	0.6	328
65	In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. British Journal of Haematology, 2006, 134, 37-44.	1.2	18
66	MLN120B, a Novel IÎºB Kinase Î² Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clinical Cancer Research, 2006, 12, 5887-5894.	3.2	130
67	Elevated Apurinic/Apyrimidinic Endonuclease Activity Significantly Contributes to DNA Instability in Multiple Myeloma.. Blood, 2006, 108, 2077-2077.	0.6	0
68	A SCID-hu in vivo model of human Waldenstrol̂m macroglobulinemia. Blood, 2005, 106, 1341-1345.	0.6	37
69	A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood, 2005, 106, 713-716.	0.6	115
70	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood, 2005, 105, 4470-4476.	0.6	59
71	Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma. Clinical Cancer Research, 2005, 11, 4251-4258.	3.2	93
72	Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone.. Blood, 2005, 106, 4447-4447.	0.6	1

#	Article	IF	Citations
73	Establishment of a Waldenstromâ€™s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. Blood, 2005, 106, 979-979.	0.6	5
74	Novel Model To Evaluate Changes in Gene Expression Profile of Myeloma Cells In Vivo Following Interaction with Human BM Microenvironment.. Blood, 2005, 106, 2490-2490.	0.6	1
75	Alkylphosphocholine Perifosine Inhibits Myeloma Cell Growth While Inducing Myeloid Hyperplasia in a Murine Myeloma Model.. Blood, 2005, 106, 1579-1579.	0.6	0
76	Novel Hydroxamic Acid-Derived HDAC Inhibitor LBH589 Potently Activates Intrinsic and Extrinsic Apoptotic Pathways, and Induces Tubulin Hyperacetylation in Multiple Myeloma.. Blood, 2005, 106, 1578-1578.	0.6	1
77	Dysfunctional T Regulatory Cells in Myeloma: Molecular Mechanisms of Dysregulation.. Blood, 2005, 106, 3462-3462.	0.6	1
78	Cytotoxic activity of the maytansinoid immunoconjugate B-B4â€“DM1 against CD138+ multiple myeloma cells. Blood, 2004, 104, 3688-3696.	0.6	122
79	A Clinically Relevant SCID-hu in Vivo Model of Human Multiple Myeloma.. Blood, 2004, 104, 2455-2455.	0.6	0
80	Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.. Blood, 2004, 104, 644-644.	0.6	0